Cancer Research UK appoints drug development director

Cancer Research UK
Appointee name
Lars Erwig

United Kingdom

Cancer Research UK has appointed Lars Erwig to director for its Centre for Drug Development, effective 1 February. Dr Erwig, who has pharmaceutical industry and academic experience, will be responsible for developing a portfolio of first-in-human trials for the centre, working closely with Cancer Research UK’s academic research and industry and biotech partners. He joins the UK charity from Johnson & Johnson where he was vice president for external innovation to develop academic and industry networks and advance external opportunities. 

Dr Erwig also had senior positions at Galvani Bioelectronics and at GSK in the experimental medicine discovery performance unit. Before joining industry, he was professor of nephrology at the University of Aberdeen with a special interest in multisystem autoimmune disease. He holds an MD from Medizinische Hochschule Hannover, Germany and a PhD in immunology from the University of Aberdeen, UK. The Centre for Drug Development’s current portfolio contains 10 small molecules and 13 biotherapeutic agents (as of September 2023).

Cancer Research UK announced the appointment on December 12, 2023.

Copyright 2024 Evernow Publishing Ltd.